Sign In
Buy AMAM
$28.00
+0 (+0%)
At Close: Jun 05, 2024
Ambrx Biopharma's ARX788 Selected For Phase 2 Adaptive Breast Cancer Trial
11:54am, Tuesday, 26'th Apr 2022
Quantum Leap Healthcare Collaborative and Ambrx Biopharma Inc (NYSE: AMAM) have announced the selection of Ambrx's antibody-drug conjugate (ADC) ARX788 for a new investigational treatment arm in t
Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022
04:05pm, Thursday, 21'st Apr 2022
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision B
Ambrx Biopharma (AMAM) Sees Hammer Chart Pattern: Time to Buy?
06:55am, Wednesday, 29'th Dec 2021
Ambrx Biopharma (AMAM) has been struggling lately, but the selling pressure may be coming to an end soon.
Ambrx Biopharma Stock (AMAM): Why The Price Jumped Today
12:51pm, Thursday, 09'th Dec 2021
The stock price of Ambrx Biopharma Inc (NYSE: AMAM) increased by over 29% during intraday trading today. This is why it happened.
Ambrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial
12:30pm, Thursday, 09'th Dec 2021
Ambrx Biopharma Inc's (NYSE: AMAM) partner in China, NovoCodex Pharmaceuticals Ltd, presented favorable safety and efficacy data from its ongoing ACE-Breast-01 Phase 1 study of ARX788 at the San A
Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference
04:30pm, Thursday, 09'th Sep 2021
SAN DIEGO--(BUSINESS WIRE)--Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference
Ambrx Announces Pricing of Initial Public Offering
11:15pm, Thursday, 17'th Jun 2021
SAN DIEGO--(BUSINESS WIRE)--Ambrx Announces Pricing of Initial Public Offering
